Bacterial Infections

Safety, Efficacy of Oral Microbiome Therapeutic Confirmed in Recurrent CDI Study

Confirmatory results were announced from a phase 3 study investigating the oral microbiome therapeutic SER-109 for the treatment of recurrent Clostridioides difficile infection (CDI). SER-109 contains purified bacterial spores of multiple Firmicute species obtained from the stool of healthy human donors. The open-label ECOSPOR IV study (ClinicalTrials.gov Identifier: NCT03183141) included a total of 263 adults with recurrent…